Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 86

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 86
---
,000 units (the
“Units”). Each Unit consists of one ordinary share, $0.0001 par value (“ordinary share”) and one right to receive
one-eighth (1/8) of one ordinary share upon the consummation of an initial business combination. The Units were sold at an offering price
of $10.00 per unit, generating gross proceeds, before expenses, of $200,000,000. We granted the underwriters a 45-day option to purchase
up to 3,000,000 additional Units to cover over-allotments, if any.

19

Simultaneously
with the closing of the IPO, we consummated the private placement with Drugs Made In America Acquisition LLC, our sponsor, of 400,000
units (the “Private Placement Units”) at a price of $10.00 per unit, for $4,000,000. The Private Placement Units are identical
to the Units sold in the IPO, except that the Private Placement Units, including the underlying securities, may not, subject to certain
limited exceptions, be transferable, assignable or salable by the sponsor until the earlier of: (i) with respect to 50% of the Private
Placement Units, the earlier of six months after the date of the consummation of our initial business combination and the date on which
the closing price of our ordinary shares equals or exceeds $12.50 per share (as adjusted for share subdivisions, share capitalizations,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after our initial
business combination and (ii) with respect to the remaining 50% of the Private Placement Units, six months after the date of the consummation
of our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a
liquidation, merger, share exchange or other similar transaction which results in all of our shareholders having the right to exchange
their ordinary shares for cash, securities or other property. The sponsor was granted certain demand and piggyback registration rights
in connection with the purchase of the Private Placement Units. No underwriting discounts or commissions were paid with respect to such
sale. The Private Placement Units were issued pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities
Act of 1933, as amended (the “Securities Act”).

Subsequently,